NextCure NXTC 深 沪
等待开盘 08-05 09:30:00 美东时间
5.04
+0.150
+3.07%
华盛通- 最 高5.175
- 今 开5.03
- 成交量 1.73万股
- 最 低 4.80
- 昨 收 4.89
- 总市值 1348.80万
- 52周最高 19.80
- 市盈率 静 --
- 换手率 0.65%
- 52周最低 2.688
- 委 比 -92.31%
- 总股本 267.62万
- 历史最高 1308.00
- 量 比 0.21
- 振 幅 7.67%
- 历史最低 2.688
- 每 手 1
- 风险率 5.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NextCure Presented New Preclinical Data In A Well-Established Model Of Osteogenesis Imperfecta Demonstrating That Treatment With NC605 Achieved Improved Bone Microarchitecture And Reduced Fracture Incidence Compared To Anti-Sclerostin Treatment
BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies
07-25 04:11
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
NextCure Inc. announced new preclinical data showing that NC605, an anti-Siglec-15 antibody, improved bone microarchitecture and reduced fracture incidence in a model of osteogenesis imperfecta (OI) compared to anti-sclerostin treatment. OI is a rare disorder with no cure; current treatments inhibit both bone loss and formation, leading to poor bone quality. NC605 inhibits bone loss and promotes new bone formation, improving density and quality. ...
07-24 20:05
Piper Sandler Maintains Overweight on NextCure, Lowers Price Target to $15
Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $36 to $15.
07-15 22:41
NextCure Enacts 1-for-12 Reverse Stock Split, Shares Begin Trading Today on Adjusted Basis
On July 14, 2025, NextCure, Inc., a Delaware corporation (the "Company"), effected a one-for-twelve (1:12) reverse stock split ("Reverse Stock Split") of the Company's common stock, par value $0.001 (the "Common Stock").
07-14 19:19
抗肿瘤创新药企「先声再明」获太平医疗健康基金投资
原标题：抗肿瘤创新药企「先声再明」获太平医疗健康基金投资 投资界（ID：pedaily2012）6月24日消息，近日，太平医疗健康基金完成了对海南先声再明医药...
06-24 14:13
超53亿！国产ADC又卖了
（转自：动脉新医药） 2025年6月16日获悉，先声药业集团（HKEX：2096）旗下的抗肿瘤创新药公司先声再明与致力于癌症创新药开发的临床阶段美国生物制药公司...
06-17 14:13
创新药出海再下一城！先声药业与NextCure达成重磅合作
6月16日，先声药业（02096）宣布，其附属公司海南先声再明医药股份有限公司已与美国生物技术公司NextCure, Inc.（NXTC.US）签署一项许可协议。
06-17 08:08
港股概念追涨丨创新药临床试验申请在30个工作日内完成审评审批，医药股利好持续发酵（附概念股）
国家药品监督管理局发布《关于优化创新药临床试验审评审批有关事项的公告（征求意见稿）》。
06-17 07:37
NextCure Enters Licensing Agreement with Simcere Zaiming
The latest announcement is out from NextCure ( ($NXTC) ). On June 13, 2025, Nex...
06-16 19:58
创新药出海再下一城！先声药业（02096）与NextCure达成重磅合作
6月16日，先声药业（02096）宣布，其附属公司海南先声再明医药股份有限公司已与美国生物技术公司NextCure, Inc.（NXTC.US）签署一项许可协议...
06-16 19:23
